In Silico Study of a-Amylase and a-Glucosidase Inhibitory Compounds in Aloe vera as Antidiabetic Agent
DOI:
https://doi.org/10.21776/ub.biotropika.2023.011.01.04Abstract
Type 2 diabetes mellitus (T2DM) is a chronic disease that poses a significant global health issue. The most commonly given drug to treat diabetes is acarbose, which works as an inhibitor of polysaccharide-degrading enzymes, such as alpha amylase dan alpha glucosidase so that the blood glucose level in T2DM patients could be reduced. This study aims to analyse five bioactive aloe vera compounds as inhibitors of alpha amylase and alpha glucosidase enzymes. This research was conducted through in silico studies based on molecular docking using PyRx 0.8 and Biovia Discovery Studio software, cytotoxicity testing through pkCSM and feasibility of medicinal materials through ADMET analysis. The results showed that hesperidin has a binding affinity of -9.1 kcal/mol against the alpha amylase enzyme. Meanwhile, acarbose, as a control, showed a binding affinity of -8.5 kcal/mol. In addition, osajin, pomiferin, cosmosiin, and hesperidin had a binding affinity of -7.8, -8.1, -7.7, and -8.8 kcal/mol, respectively. These values were also higher than acarbose (-7.3 kcal/mol). Three compounds, namely osajin, pomiferin, and aloesin, met the drug-likeness criteria and had absorption rates in the digestive tract between 31.48-96.59%. The toxicity analysis using the AMES test revealed that all compounds, except aloesin, did not exhibit properties that could potentially cause hepatotoxicity or promote mutagenesis. These results indicate that the bioactive compounds in Aloe vera have the potential to be used as antidiabetic agents through the inhibition of polysaccharide-degrading enzymes. Further research is needed to analyze the antidiabetic properties of the compounds in Aloe vera through in vivo studies with more optimal drug delivery innovations.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Biotropika: Journal of Tropical Biology
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyright and Attribution:
Articles in Biotropika: Journal of Tropical Biology are under Creative Commons Attribution-NonCommercial (CC-BY-NC) copyright. The work has not been published before (except in the form of an abstract or part of a published lecture or thesis) and it is not under consideration for publication elsewhere. When the manuscript is accepted for publication in this journal, the authors agree to the automatic transfer of the copyright to the publisher.
Journal of Biotropika: Journal of Tropical Biology is licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0).
Permissions:
Authors wishing to include figures, tables, or text passages that have already been published elsewhere and by other authors are required to obtain permission from the copyright owner(s) for both the print and online format and to include evidence that such permission has been granted when submitting their papers. Any material received without such evidence will be assumed to originate from one of the authors.
Ethical matters:
Experiments with animals or involving human patients must have had prior approval from the appropriate ethics committee. A statement to this effect should be provided within the text at the appropriate place. Experiments involving plants or microorganisms taken from countries other than the author's own must have had the correct authorization for this exportation.
